Passage BIO, Inc. 10-Q — AI Bull & Bear Analysis

Passage Bio finds itself at a crossroads where compelling clinical science meets a precarious financial state. The company has successfully validated the biological mechanism of PBFT02, but the cost of moving from a Phase 1/2 trial to a randomized registrational study is far beyond its current means. The aggressive workforce reduction and strategic review are clear signals that management is seeking an exit or a lifeline via a partnership rather than attempting to fund the full clinical path independently. Investors are essentially betting on whether the clinical data is strong enough to trigger a premium acquisition before the cash runs out. While the operational streamlining is a positive step toward making the company a more attractive target, the looming 'going concern' status gives potential buyers significant leverage to negotiate lower prices. The outcome will likely be determined by the success of the strategic alternatives review initiated in April 2026.